All News

Found 59,360 articles

• Jumo Health Celebrates Ranking on the 2022 Inc. 5000 List of Fastest Growing Companies

  8/17/2022

  Jumo Health, a global provider of age appropriate, culturally sensitive medical education resources, today announced it is among the fastest growing private companies as reported by Inc. Magazine in its prestigious Inc. 5000 list.

• ADDING MULTIMEDIA ICL and Lavie Bio Enter Strategic Collaboration to Develop Novel Bio-Stimulant Products

  8/17/2022

  ADDING MULTIMEDIA ICL and Lavie Bio Enter Strategic Collaboration to Develop Novel Bio-Stimulant Products.

• Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MMP7 for Idiopathic Pulmonary Fibrosis

  8/17/2022

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-MMP7, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce expression of matrix metalloproteinase 7 (MMP7) as a potential treatment for idiopathic pulmonary fibrosis (IPF).

• Magenta Therapeutics Appoints Michael Vasconcelles, M.D. to the Board of Directors

  8/17/2022

  Magenta Therapeutics today announced that it has appointed Michael Vasconcelles, M.D. to its board of directors.

• Omeros Corporation Receives Interim Response from FDA on Formal Dispute Resolution Request for Narsoplimab

  8/17/2022

  Omeros Corporation (Nasdaq: OMER) today announced that the United States Food and Drug Administration (FDA) provided an interim response to the company’s formal dispute resolution request submitted to the Agency in June, appealing the earlier decision by the FDA review division to issue a complete response letter for the biologics license application (BLA) for narsoplimab.

• Oyster Point Pharma Announces TYRVAYA® To Be Covered By the Largest Medicare Pharmacy Benefit Manager

  8/17/2022

  Oyster Point Pharma, Inc. today announced that the largest Medicare Pharmacy Benefit Manager in the United States will add TYRVAYA ® Nasal Spray on its Medicare Part D formularies, effective September 1, 2022.

• Independent Study Shows Cue Health's Molecular COVID-19 Test is as Accurate as a Lab-Based PCR Test

  8/17/2022

  Cue Health Inc. ("Cue") (Nasdaq: HLTH) announced today the preprint publication of an independent clinical study - the largest of its kind on asymptomatic people - demonstrating that its point of care (POC) molecular COVID-19 test, which produces results in approximately 20 minutes, is as accurate as a centralized lab-based RT-PCR.  

• Blue Water Vaccines Announces Exploration of Its Virus-Like Particle (VLP) Platform for Use in Monkeypox Vaccine Candidate

  8/17/2022

  Blue Water Vaccines Inc. today announced that the Company plans to explore the potential to develop a novel monkeypox vaccine using its norovirus shell and protrusion virus-like particle (VLP) platform.

• RedHill Biopharma Announces EU Orphan Drug Designation for RHB-204 for NTM Infections

  8/17/2022

  RedHill Biopharma today announced that the European Commission has granted Orphan Drug Designation to RHB-2041 for the treatment of nontuberculous mycobacteria (NTM) disease.

• Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand as a First and Second Booster for Adults

  8/17/2022

  Nuvaxovid™ is New Zealand's first and only protein-based COVID-19 vaccine Nuvaxovid™ can now be used as a first or second booster dose for adults aged 18 and older vaccinated with any primary series vaccine.

• Cybin and Clinilabs Granted Schedule I DEA License for CYB003 Phase 1/2a First-In-Human Clinical Trial

  8/17/2022

  Cybin Inc. and Clinilabs Drug Development Corporation today announced that the U.S. Drug Enforcement Agency (“DEA”) has granted a Schedule I license to support the first-in-human Phase 1/2a clinical trial of CYB003, a proprietary deuterated psilocybin analog that is being developed for the treatment of major depressive disorder (“MDD”).

• Ainos Announces Master Services Agreement with Swiss Pharmaceutical, Ltd. for Drug Testing, Manufacturing, and Packaging for its VELDONA Product Candidates

  8/17/2022

  Ainos, Inc. today announced it has signed a Master Service Agreement with Swiss Pharmaceutical Co., Ltd.

• Iterum Therapeutics Announces Date of 1-for-15 Reverse Share Split

  8/17/2022

  Iterum Therapeutics plc announced that it will effect a 1-for-15 reverse share split of its outstanding ordinary shares at 5.00 p.m. Eastern Time on August 17, 2022, which will be effective for trading purposes on the Nasdaq Capital Market as of the commencement of trading on August 18, 2022.

• James Mock Joins Moderna as Chief Financial Officer

  8/17/2022

  Moderna, Inc. today announced that James Mock has been appointed as Moderna's Chief Financial Officer, beginning September 6, 2022.

• Can-Fite: Reports Progress in the Development of Piclidenoson for Osteoarthritis in Pets Through its Partner Vetbiolix

  8/17/2022

  Can-Fite BioPharma Ltd. announced today that hrough a development and commercialization agreement signed with Vetbiolix in June of 2021, Piclidenoson is set to enter a clinical trial for the treatment of osteoarthritis in dogs.

• Exscientia Business Update for Second Quarter and First Half 2022

  8/17/2022

  Recent developments in the Company’s pipeline, collaborations, and operations, as well as financial results for the second quarter and first half 2022, are summarised below.

• Press Release: Sanofi provides update on amcenestrant clinical development program

  8/17/2022

  Sanofi is discontinuing the global clinical development program of amcenestrant, an investigational oral selective estrogen receptor degrader.

• UCB Partners in Health Economics and Outcomes Research to Evolve Solutions for Seizure Clusters

  8/17/2022

  UCB today announced three collaborations aimed at examining the impact of seizure clusters on patient and caregiver quality of life.

• Blueprint Medicines Announces Positive Top-line Results from PIONEER Trial of AYVAKIT® (avapritinib) in Patients with Non-Advanced Systemic Mastocytosis Achieving Primary and All Key Secondary Endpoints

  8/17/2022

  Blueprint Medicines Corporation (NASDAQ: BPMC) today announced positive top-line results from the registrational Part 2 of the PIONEER clinical trial of AYVAKIT®.

• Samsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration HUMIRA® Biosimilar HADLIMA™ (adalimumab-bwwd)

  8/17/2022

  Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) today announced the U.S. Food and Drug Administration (FDA) has approved the citrate-free, high-concentration (100 mg/mL) formulation of HADLIMA™ (adalimumab-bwwd), a biosimilar referencing HUMIRA® (adalimumab). HADLIMA will be available in pre-filled syringe and autoinjector options, and the autoinjector was specifically designed with the patient in mind